Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTOPUS: Brolucizumab in nAMD
NCT04239027Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2021
- Primary completion
- May 2022
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brolucizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Primary endpoint: Percentage Change in Choroidal Neovascularization (CNV) Lesion Area Measured by Optical Coherence Tomography-Angiography (OCT-A) From Baseline to Week 12. Started Jan 2021; status: completed.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04239027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04239027.